GILD - looks ready for a pull back. Some nice targets on GILD let's see how many we can get to. What do you think? Will break through stops and continue higher or flush? GL!
GILD trade ideas
Gilead Sciences (GILD) Soars 4.93% on Strong Q4 Earnings ReportsGilead Sciences (NASDAQ: NASDAQ:GILD ) is making waves in the biotech sector after delivering a stellar fourth-quarter earnings report that not only crushed Wall Street expectations but also set the stage for a promising 2025. The stock surged 4.50% in premarket trading on Wednesday, signaling strong investor confidence in the company’s growth trajectory.
Quarter and Optimistic Guidance
Gilead’s Q4 earnings report was nothing short of impressive. The company posted adjusted earnings of $1.90 per share, a 10.5% year-over-year increase, and handily beat analysts’ estimates of $1.74. Revenue climbed 6% to $7.57 billion, surpassing the consensus forecast of $7.15 billion.
HIV Franchise Shines Bright
Gilead’s HIV portfolio remains its crown jewel. Biktarvy, the company’s flagship HIV treatment, generated $3.8 billion in sales, up 21% year-over-year and well ahead of the $3.47 billion forecast. Descovy, another HIV drug, also outperformed expectations, with sales rising 21% to $616 million. Combined, Gilead’s HIV product sales reached $5.45 billion, up 16% from the previous year.
Looking ahead, Gilead is poised to expand its HIV franchise further with the anticipated mid-2025 launch of lenacapavir, a twice-yearly injectable for HIV prevention. The U.S. Food and Drug Administration (FDA) is expected to make a decision on the drug by mid-2024, and its approval could be a significant growth catalyst.
Oncology and Liver Disease: Steady Growth
Gilead’s oncology and liver disease segments also contributed to the strong quarter. Sales of its cell therapies for cancer treatment rose 5% to $488 million, beating expectations of $476 million. Trodelvy, a cancer drug, saw sales jump 19% to $355 million, surpassing the $324 million forecast. Liver disease treatments brought in $719 million, up 4% year-over-year.
Veklury: The Only Blemish
The only downside in Gilead’s report was Veklury, its COVID-19 treatment. Sales plummeted 53% to $337 million due to lower hospitalizations, particularly in the U.S.
Upbeat 2025 Guidance
Gilead’s bullish outlook for 2025 further fueled investor optimism. The company expects adjusted earnings of $7.70 to $8.10 per share on product sales of $28.2 billion to $28.6 billion. The midpoint of this guidance exceeds analysts’ estimates of $7.61 per share and $28.35 billion in revenue.
Technical Analysis
From a technical perspective, Gilead’s stock is showing strong bullish signals. As of Wednesday’s premarket trading, GILD is up 4.93%, poised to form a gap-up pattern upon market open.
Key Levels to Watch
- Resistance: A breakout above the 1-month high of $100 could serve as a critical catalyst for a sustained bullish run. This level represents a psychological barrier, and a decisive move above it could attract more buyers.
- Support: In the event of a pullback, immediate support lies at the 65% Fibonacci retracement level, which aligns with the $92 mark. This level could act as a springboard for renewed upward momentum.
RSI Indicates Room for Growth
The Relative Strength Index (RSI) stands at 55, indicating that the stock is neither overbought nor oversold. This suggests there is ample room for further upside, especially if the broader market sentiment remains favorable.
Conclusion
Gilead Sciences (GILD) is firing on all cylinders, with a strong Q4 earnings beat, robust guidance for 2025, and a promising pipeline. The company’s leadership in the HIV market, coupled with its growing presence in oncology and liver disease, positions it well for long-term growth. From a technical standpoint, the stock is primed for a breakout, with key resistance and support levels offering clear markers for traders and investors.
Harmonic Within a Harmonic on Gilead. GILDThey are crooked looking, but are present. Another tangent of evidence on the obvious fractal nature of markets. That thick candle to us confirms break of trend and the underlying indicators are also suggestive. It is prudent to note that the indicator readings have been formed by price action, volume and volatility immediately coming prior to that candle. Good luck out there!
GILD Gilead Sciences Options Ahead of EarningsAnalyzing the options chain and the chart patterns of GILD Gilead Sciences prior to the earnings report this week,
I would consider purchasing the 89usd strike price Calls with
an expiration date of 2024-11-15,
for a premium of approximately $2.91.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Gilead Sciences (GILD): Will Support Hold or Will We See a Drop?We've neglected Gilead Sciences for a while, but it's time for an update. Unfortunately, our entry looking back wasn't ideal, as the stock has fallen below the 61.8% retracement level. It found support just below the 78.6% level, which marks the bottom of our range. This level was precisely touched, and we saw a relatively good movement upward from there.
However, the outlook remains uncertain. We hope that the stock does not fall below this range bottom, as it would prompt us to consider cutting it. Our first take-profit target is at the range high around $86.5, but reaching this level will take time as Gilead Sciences is currently underperforming.
Unlike most other stocks, Gilead Sciences operates in the research sector, not the tech sector. This means it follows a different cycle and is influenced by different capital flows. It tends to perform well when tech stocks do poorly. If tech stocks remain bullish, Gilead Science might continue to struggle. However, if there's a shift, Gilead Science could reverse and potentially reach up to $123, though this is quite far off.
We are holding our position for now, hoping not to cut if the stock falls out of the range. If it does, we will take necessary action.
Gilead Sciences (GILD): Pattern Still Intact—What’s the Plan?Let’s quickly review our open position in $GILD. We’ve managed to turn the whole chart around, and I hope everyone who bought in had the strength to sit it out. It was a close call with the stop loss, but now we’re up significantly, and we’ve moved our stop loss closer to $65.46. So far, we’re up 17%, and we don’t want to dictate when to take profits. If you’re in, do your own research and take profits whenever you feel comfortable—it's all up to you 👍.
If you take a closer look, you’ll see that NASDAQ:GILD has been following a nice upward pattern: a surge, then three candles down, then another surge. I’m not sure how long this pattern will hold, but as long as we don’t retrace too much, we should be fine. I also like that we’re respecting all the key levels. The RSI is about to be overbought, so we might see another three candles down, but this time it could be a deeper pullback.
We’ll see how it plays out, but we’re very pleased with this swing trade so far. Congratulations to everyone who’s been riding this wave 🍾.
Gilead Sciences (GILD): First Take Profit in a High RangeGilead Sciences is now back trading at the high end of its range, and we’ve decided to take our first profit here. It’s crucial to respect range-bound trading, and there is a strong possibility of a pullback at this point. However, we don’t expect this pullback to reach the lower end of the range again but rather settle in the middle. If NASDAQ:GILD reclaims this range high, it could provide even more upside and new opportunities.
We are also raising our stop loss to $65.80 to lock in gains. Gilead serves as our "natural hedge" against broader risk-on market conditions, and with a 40% bounce from the range low at the same time the S&P 500 is hitting new all-time highs, it’s clear that Gilead can benefit as well.
We’re keeping a close eye on this stock, and if another opportunity arises, we’ll be ready to act.
Swing Trade Potential Following Completed BottomNASDAQ:GILD has completed its bottom AND sustained the run up from the bottom completion, which provides strong support. The stock is now heading toward the previous resistance highs from January; this is not strong resistance. The type of sideways trend developing now builds energy that can easily move above that weaker resistance. Swing trade watch. Earnings are in a month.
GILD potential Buy setupReasons for bullish bias:
- Price gave LH breakout
- Strong bullish divergence
- Price bounce from support zone
Here are the recommended trading levels:
Entry Level(CMP): 68.30
Stop Loss Level: 60.81
Take Profit Level 1: 76.05
Take Profit Level 2: 83.67
Take Profit Level 3: Open
GILD is BullishPrice was in a strong downtrend, however the bulls woke up and won control of the price action, following bullish RSI divergence on daily time frame, now first higher high and higher low are defined, and if previous higher high is broken, we can expect a bullish rally according to Dow theory. Targets are mentioned on the chart.
Bullish reversal is a clear confirmationNASDAQ:GILD had a strong bullish buying pressure at the bottom with the support of a volume spike. Furthermore, it has broken out of the downtrend line. Double bottom formation is confirmed and Mid-term stochastic is showing confirmation of oversold together with divergence.
Hence, we will buy on market spot upon open or a retracement to 69.11 or 64.85.
GILD will be selected for the new Tamiflu vaccine for Pandemic2It's no secret the elite are manufacturing pandemics to herd, destroy and remake society into a neofeudal system controlled by social credit scores. The next pandemic will be H1N1 which has already been shared within the news that milk in the markets has trace amounts of (no worry they say!).
After the establishment rolls out bird-flu for everyone's summer bingo card - Gilead Sciences, the only company that manufactures Tamiflu with options, will be selected to mass create these new vaccines.
The call options on this company are going crazy right now, July, August have a ton of OTM calls being bought, almost like someone is expecting this company to get the greenlight on something major. You could effectively buy .05 OTM calls on this company, but I'd wait a little longer. The TTM squeeze shows the last leg down is being finished. If the market's capitulate a little more, this would be a perfect time to buy those calls for this company.
GILD potential Buy setupReasons for bullish bias:
- Safe entry at LH breakout
- Price bounce from support
- Bullish divergence
- Positive Earnings
Here are the recommended trading levels:
Entry Level(Buy stop): 68.59
Stop Loss Level: 64.05
Take Profit Level 1: 71.98
Take Profit Level 2: 84.79
Take Profit Level 3: Open
GILD falling wedgeHi traders,
Focusing on Gilead Sciences, Inc. (ticker symbol: GILD), we can see that it has formed a
falling wedge pattern over the past few weeks, indicating a potential bullish reversal.
Despite recent challenges, there are compelling reasons to consider a long position in this
stock.
Gilead Sciences has been a key player in the pharmaceutical industry, known for its
innovative treatments in areas such as HIV/AIDS, hepatitis, and more recently, COVID-19.
Despite recent market pressures, GILD fundamental strength remains intact, supported
by its diverse portfolio of blockbuster drugs and ongoing research and development efforts.
The falling wedge pattern, coupled with the oversold Relative Strength Index (RSI) suggests
that the stock is undervalued and may be ripe for a reversal. As the stock approaches the
apex of the falling wedge, and the key support level, we expect the trend reversal. The breakout above the upper trendline could signal a bullish move.
Furthermore, recent news indicates that Gilead Sciences is exploring strategic initiatives to
enhance its pipeline and drive future growth. This includes potential partnerships,
acquisitions, and advancements in its drug development programs, which could serve as
catalysts for a turnaround in the stock's performance.
As the breakout of the falling wedge pattern becomes imminent, considering a long position
upon confirmation of a break above the upper trendline may present an attractive
opportunity for traders seeking to capitalize on the potential bullish reversal.
Buy once the breakout occurs.
3 take profit levels / targets are shown on the chart
Gilead Sciences (GILD): Chances in Pharma Beyond TechGilead Sciences (GILD): NASDAQ:GILD
We're aiming to diversify our portfolio beyond just tech stocks and the tech sector. We're now focusing on companies in the pharmaceutical industry, such as Gilead Sciences. Analyzing the weekly chart, we observed the largest surge since 2010 for Wave (3). We believe we've also completed Wave (4) at $56.56. The peak was at $123.27, marking our all-time high.
This figure is our target for the minimum achievement for Wave 3. It's crucial, and significantly, we anticipate a high selling pressure at this level. Zooming in, we presume we are in Wave 2, expected to conclude between 61.8% and 78.6% retracement. This positions us with a relatively favorable risk-to-reward ratio on the daily chart. Should we drop below this 78.6% retracement level, we could fall back to $56. If that happens, we'll face a problem, potentially falling further for Wave (4) to a maximum of $30. If this decline doesn't materialize, we'll continue to anticipate an upward movement.
GILD Gilead Sciences Options Ahead of EarningsIf you haven`t bought GILD before the previous earnings:
Then analyzing the options chain and the chart patterns of GILD Gilead Sciences prior to the earnings report this week,
I would consider purchasing the 80usd strike price Calls with
an expiration date of 2024-6-21,
for a premium of approximately $3.10.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Gilead's Trodelvy Faces Setback in Lung Cancer Trial
In a recent announcement, Gilead Sciences ( NASDAQ:GILD ) disclosed disappointing results from a late-stage trial evaluating its antibody-drug conjugate, Trodelvy, in second-line treatment for advanced non-small cell lung cancer (NSCLC). The Phase 3 study, aiming to expand Trodelvy's applications, did not meet its primary goal of significantly improving survival for previously treated patients. Despite a noted three-month survival benefit for a subgroup, the overall outcome fell short of statistical significance. This setback raises questions about Trodelvy's potential in lung cancer and underscores the challenges in developing effective treatments for this complex disease.
The Trial and Its Implications:
The trial involved 603 patients with metastatic or advanced NSCLC who had experienced disease progression despite standard platinum-based chemotherapy and checkpoint inhibitor treatment. Gilead reported that patients receiving Trodelvy exhibited longer survival compared to those on chemotherapy, but the difference did not reach statistical significance. Notably, a subgroup of patients who did not respond to their last checkpoint inhibitor treatment showed a more than three-month survival benefit. Gilead plans to discuss these results with regulators and present the full data at an upcoming medical meeting, indicating a commitment to transparent communication and a thorough examination of the findings.
Exploring Trodelvy's Potential:
Despite the setback, Gilead ( NASDAQ:GILD ) remains optimistic about Trodelvy's potential in metastatic NSCLC. The company emphasizes the drug's positive impact on a specific patient subgroup and expresses confidence in Trodelvy's broader lung cancer clinical development program. Gilead's Chief Medical Officer, Merdad Parsey, highlights ongoing Phase 2 and 3 trials investigating Trodelvy in combination with Keytruda as an initial treatment for NSCLC patients. The company's dedication to understanding the drug's effects and exploring potential pathways reflects a commitment to advancing cancer care.
Trodelvy's Safety Profile and Current Approvals:
Gilead ( NASDAQ:GILD ) reassures stakeholders by affirming that Trodelvy's safety profile aligns with prior studies, with common adverse events being neutropenia (low white blood cell counts) and diarrhea. It's worth noting that Trodelvy is already approved by U.S. regulators for specific advanced breast cancer and bladder cancer indications. In the first nine months of the previous year, Gilead reported sales of $765 million for Trodelvy, attesting to its commercial success in the approved indications.
Future Prospects and Challenges:
Despite the setback in the second-line lung cancer trial, Gilead remains resilient in its pursuit of innovative solutions for oncology. The ongoing front-line Phase 3 trial combining Trodelvy with Keytruda suggests a strategic focus on exploring novel treatment approaches. However, as emphasized by Parsey, results from this trial are not expected for at least a couple of years, highlighting the prolonged timeline inherent in clinical research.
Conclusion:
Gilead's ( NASDAQ:GILD ) recent trial results for Trodelvy in second-line NSCLC treatment present a nuanced narrative of challenges and opportunities in the evolving landscape of cancer therapeutics. The company's commitment to transparency, ongoing research, and exploration of combination therapies underscores the complexity of addressing lung cancer, one of the most formidable challenges in oncology.
As the full dataset becomes available and discussions with regulators unfold, stakeholders will eagerly anticipate the next chapter in Trodelvy's journey, hoping for breakthroughs that could reshape the future of lung cancer treatment.
